Get to Know About the Molecular Cytogenetic Analysis for Acute Lymphoblastic Leukemia. This test will diagnose and monitor the treatment response of patients.

1. Cytogenetics
To diagnose and monitor the treatment response of patients with B-cell
acute lymphoblastic leukemia (B-ALL).
Fluorescence In Situ Hybridization (FISH).
This test includes culture of blood / bone marrow cells, followed by
analysis of special sites of the chromosome using fluorescent probes.
BCR-ABL1, t(9:22)(q34;q11).
4 working days.
Bone marrow (Preferably)/ Peripheral blood.
3-4 ml bone marrow / 4 ml blood in green top heparin tube.
Label the vacutainer with patient’s name and specimen type.
The specimen should be shipped at 18-25°C, do not freeze.
It should reach the lab within 24 hours of collection
(preferably at the earliest). In case of delay, sample
to be stored on the door shelf of the refrigerator.
Complete blood count and bone marrow/ peripheral blood blast percentage must be provided.
Specify detailed clinical history, collection date & time of sample withdrawn on test request form*.
BCR-ABL1, t(9:22)(q34;q11)
¤ Present in 25% adult B-ALL
and 2-4% Pediatric B-ALL cases.
¤ Results in chimeric fusion protein
with constitutive tyrosine kinase activity.
¤ Presence of BCR-ABL1 fusion
gene confers a poor prognosis.
Test Purpose :
Methodology :
Testing Procedure :
Gene Analyzed :
Turn Around Time :
Specimen Type :
Specimen Volume :
Collection
instructions :
Specimen Transport :
Mandatory
Requirements :
Significance of :
Gene tested
Molecular Cytogenetic Analysis for
Acute Lymphoblastic Leukemia

2. Corporate Office & Referral Laboratory,
DDRC SRL Towers, Panampilly Nagar, Kochi-682 036
Ph: +91 484 2318222, 2318223
email: info@ddrcsrl.com
www.ddrconline.com, www.ddrclab.com
94977 17850
94977 17842
Highlights of the Test:
¤ Identification of specific BCR-ABL1 gene rearrangement
is critical for disease evaluation, optimal risk stratification and
treatment planning.
¤ BCR-ABL1 fusion gene amplification status, one of the prime
factors for drug resistance and adverse prognosis in ALL, is
also evaluated by this assay.
¤ This test is able to identify masked and variant Ph
(Philadelphia Chromosome) translocations which are not
detected by conventional cytogenetics and PCR primers.
¤ A single FISH assay can cover all the splice variants of
BCR-ABL1 fusion gene including b2a2 or b3a2 coding for
p210; e1a2 coding for p190; e19a2 (c3a2) coding for p230.
¤ Sensitivity and Accuracy: For initial diagnosis, 100-200
interphase nuclei are counted. For therapeutic response
analysis, with a previously abnormal result, up to 500
interphase nuclei may be counted.
¤ CE-IVD approved LSI BCR/ABL1 dual color, dual fusion
translocation probe kit is used for the assay.
Note:
A repeat sample may be needed in case
of culture failure.
If further testing is required, additional
charges may be incurred.
*Samples shall be rejected if above
details are not provided.